## Verdict

verdict: PASS

```json
{"phase":"8.5","verdict":"PASS","iterations":1,"mode":"deep","practitioner_layer":{"path":"vault/library/peptides/ss-31/practitioner-layer.md","present":true,"compounding_sheets_count":0,"named_physicians_count":2,"has_bibliography":true,"has_self_check":true},"non_english_layer":{"path":"vault/library/peptides/ss-31/non-english-layer.md","present":true,"languages_surveyed":["Russian","Chinese","Japanese"],"has_bibliography":true,"has_self_check":true},"halt_reasons":[]}
```

## Prose Detail

### Practitioner Layer (`vault/library/peptides/ss-31/practitioner-layer.md`)

**Present:** YES.

**Bibliography:** YES — `## Bibliography` section present (references [1]–[11]).

**Self-check:** YES — `## Self-Check` section present at end of document.

**Compounding data sheet requirement (explicit-absence form):**
The document contains an explicit "Compounding-Pharmacy Data Sheet Search (Gate Finding)" subsection (under `## Compounding Status After FDA Approval`) with the exact gate finding statement: *"NO admissible compounding-pharmacy clinical data sheet was located for compounded elamipretide / SS-31."* The vendor/pharmacy search list is comprehensive and documented:

1. Empower Pharmacy
2. Tailor Made Compounding / Infiniwell
3. Hallandale Pharmacy
4. Belmar Pharma Solutions
5. APS (Applied Pharmacy Services)
6. Strive Pharmacy
7. Better Med Spa (offers product but no primary-literature-citing monograph)
8. Real Peptides (research-chemical vendor)
9. Generic "SS-31 data sheet / monograph" PDF queries (major search engines)

That is 8 named pharmacies/vendors plus a generic query class — satisfying the explicit no-sheet + searched-vendor-list requirement. `compounding_sheets_count = 0` is correct and admissible.

**Forzinity prescribing pathway anchored on FDA PI:** YES — Section `## Approved Prescribing: FORZINITY (Barth Syndrome)` is anchored to source [1] tagged `regulatory`, citing DailyMed NLM set ID 146bf34c-76f2-48db-ac07-fb29cce2cd75, NDA215244, all dosing/monitoring/safety parameters grounded to the PI.

**Post-approval §503A "essentially a copy" restriction:** YES — Section `## Compounding Status After FDA Approval: A Restricted Pathway / The "Essentially a Copy" Doctrine (503A)` documents this explicitly, citing [3] (FDA guidance on essentially-a-copy doctrine), explains that Forzinity's October 2025 approval subjects compounding to this restriction, and states that no blanket authorization to compound elamipretide for off-label longevity use exists. The 503B pathway restriction is also addressed. Self-check reiterates this under "Compounding restriction disclosed honestly."

**Named prescribers found: 2**
- [10] Dr. Raj Singh, MD (rsinghmd.com, March 24, 2025) — tagged `practitioner_protocol`, tier 2.7
- [11] Kiara DeWitt, BSN, RN, CPN (InjectCo Medical Aesthetics, May 8, 2026) — tagged `practitioner_protocol`, tier 2.7

Both carry name + venue + date; Better Med Spa is tagged `anecdote_aggregate` and is not a named prescriber. `named_physicians_count = 2`.

---

### Non-English Layer (`vault/library/peptides/ss-31/non-english-layer.md`)

**Present:** YES.

**Bibliography:** YES — `## Bibliography` section present as a table with all 5 Chinese primaries (C1–C5), two explicit none-located rows (R-none, J-none), and two landscape entries.

**Self-check:** YES — `## Self-check` section present at end of document with checkmarks covering all required verification items.

**Languages surveyed:** Chinese, Russian, Japanese — all three present with explicit per-language findings:

- **Chinese:** 5 admissible Chinese-language primaries located (C1–C5). Topics: lens epithelial apoptosis (C1, 2015), sepsis vascular permeability in rats (C2, 2018), hindlimb I/R in mice (C3, 2018), sepsis acute liver injury in mice (C4, 2022), sepsis AKI in rodents (C5, ~2021). C1 and C4 have DOIs; C2 has a stable journal-publisher URL; C3 and C5 have stable yiigle.com cmaid identifiers. `languages_surveyed` includes Chinese with explicit findings.

- **Russian:** 0 admissible primaries. Searched CyberLeninka.ru, eLibrary.ru, PubMed (Russian language filter: 0 confirmed), Google Scholar, Yandex. Only non-admissible content found: Russian Wikipedia (all 17 refs English-language), commercial vendor pages, one 401-blocked wiki mirror. Explicit none-located stated with full search-term list in Cyrillic.

- **Japanese:** 0 admissible primaries. Searched J-STAGE, CiNii Research, J-GLOBAL, PubMed (Japanese language filter: 0 confirmed). Only trace found: J-GLOBAL machine-translation metadata record of Mitchell et al. English bioRxiv (language tag = English, confirmed non-Japanese primary). Explicit none-located stated with full search-term list in Japanese characters.

**Verdict rationale for PASS:** All structural requirements met. Both files exist; each has `## Bibliography` and a self-check section. Practitioner layer satisfies the data-sheet gate via the explicit-absence form with 8+ named searched vendors. Non-English layer covers ≥3 languages (Chinese + Russian + Japanese) with explicit per-language findings and a documented non-fabricated bibliography. No halt conditions present.
